As a result, the combination of adagrasib (MRTX849) with EGFR or ERBB inhibitors was significantly better than single agents in xenograft models of KRASG12C-mutant H2122 (NSCLC) and KYSE-410 (esophageal carcinoma) (31). Here, EGFR is linked to non-small cell lung carcinoma.